By Associate Professor Anthony Michael Joshua

Journal articles

Luckett T; Ng CA; Lai-Kwon J; Kee D; Mulhern B; Joshua AM, 2025, 'Uncertainty and hope in people with metastatic uveal melanoma in the era of immunotherapy and targeted treatments: a theory-based qualitative study', BMC Cancer, 25, http://dx.doi.org/10.1186/s12885-025-14368-6

Williams C; Inderjeeth AJ; Hong W; McKenzie J; Anton A; Weickhardt A; Wong S; Shapiro J; Parente P; Goh J; Torres J; Smith A; Joshua A; Brown S; Steer C; Johns J; Gibbs P; Tran B; Azad AA, 2025, 'Treatment patterns and outcomes for younger patients with metastatic castration-resistant prostate cancer (mCRPC); An Australian prospective registry study', Clinical Genitourinary Cancer, 23, http://dx.doi.org/10.1016/j.clgc.2025.102345

Kwan EM; Ng SWS; Tolmeijer SH; Emmett L; Sandhu S; Buteau JP; Iravani A; Joshua AM; Francis RJ; Subhash V; Lee S-T; Scott AM; Martin AJ; Stockler MR; Donnellan G; Annala M; Herberts C; Davis ID; Hofman MS; Azad AA; Wyatt AW; TheraP Investigators and the ANZUP Cancer Trials Group , 2025, 'Lutetium-177-PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial.', Nat Med, http://dx.doi.org/10.1038/s41591-025-03704-9

Lin KL; Talmor B; Crumbaker M; Joshua A, 2025, 'A Review of Hot Flash Management in Patients with Prostate Cancer.', J Clin Endocrinol Metab, http://dx.doi.org/10.1210/clinem/dgaf302

Lin H-M; Scheinberg T; Portman N; Kim RMN; Mellor R; Hunyh K; Faulkner AN; Mellett NA; Davis ID; Martin A; Sullivan D; Joshua A; McJannett M; Subhash V; Yip S; Azad AA; Marschner IC; North SA; McDermott RS; Chi KN; Stockler MR; Sweeney CJ; Meikle PJ; Horvath LG, 2025, 'Association of the circulating lipid panel, PCPro, with clinical outcomes in metastatic hormone-sensitive prostate cancer: post-hoc analysis of the ENZAMET Phase 3 randomised trial (ANZUP 1304).', Ann Oncol, http://dx.doi.org/10.1016/j.annonc.2025.05.529

Lucassen MJJ; Bergmann P; Husson O; Banerji U; Basu B; Melero I; Calvo E; Cassier PA; Drilon A; Fong PC; Garralda E; Joshua AM; Lin CC; Lopez J; Moreno V; Minchom A; Plummer R; Postel-Vinay S; Spreafico A; Shimizu T; Yap TA; Yap C; De Bono JS; Steeghs N, 2025, 'Barriers to publishing early phase clinical trials: the oncologists’ perspective', Oncologist, 30, http://dx.doi.org/10.1093/oncolo/oyaf042

Chambers CR; Watakul S; Schofield P; Howell AE; Zhu J; Tran AMH; Kuepper N; Reed DA; Murphy KJ; Channon LM; Pereira BA; Tyma VM; Lee V; Trpceski M; Henry J; Melenec P; Abdulkhalek L; Nobis M; Metcalf XL; Ritchie S; Cadell A; Stoehr J; Magenau A; Chacon-Fajardo D; Chitty JL; O’Connell S; Zaratzian A; Tayao M; Silva AD; Lyons RJ; Goldstein LD; Dale A; Rookyard A; Connolly A; Crossett B; Tran YTH; Kaltzis P; Vennin C; Dinevska M; Croucher DR; Samra J; Mittal A; Weatheritt RJ; Philp A; Monte-Nieto GD; Zhang L; Enriquez RF; Cox TR; Shi YCC; Pinese M; Waddell N; Sim HW; Chtanova T; Wang Y; Joshua AM; Chantrill L; Jeffry Evans TR; Gill AJ; Morton JP; Pajic M; Christ D; Herzog H; Timpson P; Herrmann D, 2025, 'Targeting the NPY/NPY1R signaling axis in mutant p53–dependent pancreatic cancer impairs metastasis', Science Advances, 11, http://dx.doi.org/10.1126/sciadv.adq4416

Conduit C; Inderjeeth AJ; Allen R; Martin AJ; Parulekar W; Mulroe E; McJannett M; Zielinski RR; Thomson A; Tan TH; Sandhu SK; Reaume MN; Pook DW; North SA; Marx GM; Joshua A; Horvath L; McDermott R; Chowdhury S; Chi KN; Zhang AY; Stockler MR; Davis ID; Sweeney CJ, 2025, 'Enzalutamide with standard first-line therapy for metastatic hormone-sensitive prostate cancer: a plain language summary of the ENZAMET trial (ANZUP 1304)', Future Oncology London England, 21, pp. 627 - 636, http://dx.doi.org/10.1080/14796694.2024.2440277

Jafri Z; Zhang J; O'Meara CH; Joshua AM; Parish CR; Khachigian LM, 2025, 'Interplay between CD28 and PD-1 in T cell immunotherapy', Vascular Pharmacology, 158, http://dx.doi.org/10.1016/j.vph.2024.107461

Emmett L; Subramaniam S; Crumbaker M; Joshua AM; Sandhu S; Nguyen A; Weickhardt A; Lee ST; Ng S; Francis RJ; Goh JC; Pattison DA; Tan TH; Kirkwood ID; Gedye C; Rutherford NK; Kumar ASR; Pook D; Ramdave S; Nadebaum DP; Voskoboynik M; Redfern AD; Macdonald W; Krieger L; Schembri G; Chua W; Lin P; Horvath L; Bastick P; Butler P; Zhang AY; McJannett M; Thomas H; Langford A; Hofman MS; Martin AJ; Davis ID; Stockler MR; Nguyen A; Ravi Kumar AS; Lin P; Butler P; Martin AJ; Zebic D; Mak B; Tankard N; Rana N; Cusick T; Thompson J; Oakes S; Niu C; Thein T; Ford K; Ristevski N; Yip S; Bills M, 2025, 'Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial', Lancet Oncology, 26, pp. 291 - 299, http://dx.doi.org/10.1016/S1470-2045(25)00009-9

Crumbaker M; Shekar S; Lawrence MG; Goldstein LD; Yam AO; Downton T; Begbie S; Zielinski R; Fox W; Araiza N; Yousif J; Ratnayake L; Antonarakis ES; Denmeade SR; Joshua AM, 2025, 'A phase II single arm prospective study of high dose testosterone in combination with carboplatin chemotherapy in late line metastatic castrate-resistant prostate cancer (HIGH-TeCH study).', Journal of Clinical Oncology, 43, pp. 218 - 218, http://dx.doi.org/10.1200/jco.2025.43.5_suppl.218

Crumbaker M; Krieger L; Pook DW; Davis ID; Fontela A; Oldmeadow C; Hurwitz J; Inderjeeth AJ; Dhillon HM; Downton T; Marx GM; Shekar S; Antonarakis ES; Denmeade SR; Anton A; Tan TH; Sharma S; Goh JC; Horvath L; Joshua AM, 2025, 'Bipolar androgen therapy (BAT) for nonmetastatic castration-resistant prostate (nmCRPC) cancer progressing on darolutamide: Working Out M0 BAT (WOMBAT; ANZUP 2201).', Journal of Clinical Oncology, 43, http://dx.doi.org/10.1200/jco.2025.43.5_suppl.tps298

Scheinberg T; Kench JG; Ferguson P; Sutherland S; Stockler MR; Mahon KL; Stricker P; Joshua AM; Woo H; Thanigasalam R; Ahmadi N; Marx GM; Davis ID; Sengupta S; Leslie S; Centenera MM; Butler L; Horvath L, 2025, 'LEEP: A randomised, window of opportunity, neoadjuvant trial examining the pharmacodynamic effects of ribociclib prior to radical prostatectomy for high-risk, localised prostate cancer.', Journal of Clinical Oncology, 43, pp. 392 - 392, http://dx.doi.org/10.1200/jco.2025.43.5_suppl.392

Emmett L; Subramaniam S; Crumbaker M; Nguyen A; Joshua AM; Weickhardt AJ; Lee ST; Ng S; Francis RJ; Goh JC; Pattison DA; Tan TH; Kirkwood ID; Sandhu S; Zhang AY; Hofman MS; Thomas H; Martin AJ; Davis ID; Stockler MR, 2025, 'Overall survival and quality of life with [ ¹⁷⁷ Lu] Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in poor-risk, metastatic, castration-resistant prostate cancer in ENZA-p (ANZUP 1901).', Journal of Clinical Oncology, 43, pp. 17 - 17, http://dx.doi.org/10.1200/jco.2025.43.5_suppl.17

Lin KL; Shekar S; Crumbaker M; Joshua AM, 2025, 'Neurokinin-3 Receptor Antagonism for Refractory Hot Flashes in Men', New England Journal of Medicine, 392, pp. 202 - 203, http://dx.doi.org/10.1056/NEJMc2412361

Liu J; Farrow M; Seymour L; Desai J; Loong HH; Ivy P; Koyoma T; Cook N; Blagden S; Garralda E; Massard C; Tolcher AW; Adashek JJ; Zhang L; Zhao S; Shen L; Kurzrock R; El-Deiry WS; Subbiah V; Joshua AM, 2025, 'Accelerating the Future of Oncology Drug Development: The Role of Consortia in the Delivery of Precision Oncology Early Phase Clinical Trials', Journal of Clinical Oncology, http://dx.doi.org/10.1200/JCO-24-01534

Pham JP; Staeger R; Joshua AM; Liu J; da Silva IP; Dummer R; Goldinger SM, 2025, 'An updated review of immune checkpoint inhibitors in cutaneous oncology: Beyond melanoma', European Journal of Cancer, 214, http://dx.doi.org/10.1016/j.ejca.2024.115121

Rollin SPG; Lawrence MG; Joshua AM; Selth LA, 2025, 'Friend or foe? Deciphering androgen receptor action to improve bipolar androgen therapy for prostate cancer', Endocrine Related Cancer, 32, http://dx.doi.org/10.1530/ERC-24-0208

Lawrence MG; Keerthikumar S; Townley SL; Clark AK; Cuffe GB; Laven-Law G; Hanson AR; Shrestha RK; Knutson TP; Richards MG; Teng L; Choo N; Crumbaker M; Joshua AM; Corey E; Nelson PS; Dehm SM; Risbridger GP; Tilley WD; Hickey TE; Taylor RA; Selth LA, 2025, 'Reprogramming of Androgen Receptor Activity in Castration-resistant Prostate Cancer is Shaped by Truncated Variants', European Urology Focus, http://dx.doi.org/10.1016/j.euf.2025.03.017

Dimitriou F; Orloff MM; Koch Hein EC; Cheng PF; Hughes IF; Simeone E; Montazeri K; Grover P; Mehmi I; Gerard CL; Gaudy-Marqueste C; Grob JJ; Michielin O; Hamid O; Long GV; Sullivan R; Kapiteijn E; Johnson DB; Ascierto PA; Joshua AM; Carvajal RD; Butler MO; Hassel JC; Dummer R, 2025, 'Treatment sequence with tebentafusp and immune checkpoint inhibitors in patients with metastatic uveal melanoma and metastatic GNA11/GNAQ mutant melanocytic tumors', European Journal of Cancer, 214, http://dx.doi.org/10.1016/j.ejca.2024.115161

El-Deiry WS; Bresson C; Wunder F; Carneiro BA; Dizon DS; Warner JL; Graff SL; Azzoli CG; Wong ET; Cheng L; Mani SA; Safran HP; Williams C; Meissner T; Solomon B; Rubin E; Porgador A; Berchem G; Saintigny P; Onn A; Bar J; Berger R; Gantenbein M; Chen Z; de Pádua Souza C; Reis RMV; Sekacheva M; Cervantes A; Dahut WL; Annunziata CM; Gober K; Musallam KM; Al-Shamsi HO; Abu-Gheida I; Salazar R; Limaye S; Aref AT; Reddel RR; Al Homsi MU; Rouf A; Dermime S; Al Suwaidi J; Vlad C; Buiga R; Al Omari A; Abdel-Razeq H; Oñate-Ocaña LF; Nielsen FC; Graham L; Rueter J; Joshua AM; Girda E; Libutti S; Riedlinger G; Salem ME; Farhangfar CJ; Mesa RA; Faltas BM; Elemento O; Pramesh CS; Sengar M; Aoyama S; Ikeda S; Berindan-Neagoe I; Gaddipati H; Kulkarni M; Auzias E; Gerogianni M; Wolikow N; Istolainen S; Schlafrig P; Frankel NZ; Ferraro AR; Palma J; Gimenez AP; Hernando-Calvo A; Felip E; Tsimberidou AM; Herbst RS; Tabernero J; Schilsky RL; Liu J; Lussier Y; Raynaud J; Batist G; Magidi S; Kurzrock R, 2025, 'Worldwide Innovative Network (WIN) Consortium in Personalized Cancer Medicine: Bringing next-generation precision oncology to patients', Oncotarget, 16, pp. 140 - 162, http://dx.doi.org/10.18632/oncotarget.28703

Sandhu S; Subramaniam S; Thomas H; Tan TH; Goh JC; Dhiantravan N; Weickhardt AJ; Joshua AM; Kirkwood ID; Lee ST; Gedye C; Nguyen A; Pattison DA; Alipour R; Francis RJ; Hofman MS; Martin AJ; Stockler MR; Davis ID; Emmett L, 2025, '¹⁷⁷ Lu-PSMA-617 with ipilimumab (ipi) and nivolumab (nivo) in metastatic castration-resistant prostate cancer (mCRPC): An investigator-initiated phase 2 trial (EVOLUTION; ANZUP2001).', Journal of Clinical Oncology, 43, pp. 5016 - 5016, http://dx.doi.org/10.1200/jco.2025.43.16_suppl.5016

Sacco JJ; Moser JC; Betof Warner A; Sullivan RJ; Davar D; Shoushtari AN; Carvajal RD; Patel SP; Joshua AM; Hassel JC; Navarro M; Marpadga R; Gullo G; Orloff MM, 2025, 'A randomized, phase 2/3 clinical trial investigating RP2 plus nivolumab vs ipilimumab plus nivolumab in immune checkpoint inhibitor-naïve patients with metastatic uveal melanoma.', Journal of Clinical Oncology, 43, http://dx.doi.org/10.1200/jco.2025.43.16_suppl.tps9597

Horvath L; Lin H-M; Davis ID; Martin AJ; Yeung N; Kim RMN; Portman N; Joshua AM; McJannett MM; Subhash V; Yip S; North SA; McDermott RS; Chi KN; Stockler MR; Sweeney C, 2025, 'Association of circulating immune and metabolic markers with clinical outcomes in the ENZAMET trial (ANZUP 1304).', Journal of Clinical Oncology, 43, pp. 5093 - 5093, http://dx.doi.org/10.1200/jco.2025.43.16_suppl.5093

Munzur AD; Herberts C; Kwan EM; Emmett L; Sandhu S; Buteau JP; Iravani A; Joshua AM; Francis RJ; Lee ST; Scott AM; Martin AJ; Stockler MR; Zhang AY; Williams SG; Bacon JVW; Azad A; Davis ID; Hofman MS; Wyatt AW, 2025, 'Clonal hematopoiesis (CH) in participants with metastatic castration-resistant prostate cancer (mCRPC) receiving ¹⁷⁷ Lu-PSMA-617 or cabazitaxel: An exploratory post-hoc analysis of a randomized phase II trial (TheraP; ANZUP 1603).', Journal of Clinical Oncology, 43, pp. 5020 - 5020, http://dx.doi.org/10.1200/jco.2025.43.16_suppl.5020

Lemech CR; Cosman R; Humphries TG; Kichenadasse G; Richardson GE; Nagrial A; Teng C; Liu J; Joshua AM; Cohen H; Mo J; Harvey K; Zhang H; Ling Z; King N; Barnett M; Cioffi M; Maurer MA; Getts D; Swarbrick A, 2025, 'First-in-human mRNA CAR therapy: Correlative biomarker analysis from the MT-302 phase 1 study targeting TROP2 in patients with advanced epithelial tumors.', Journal of Clinical Oncology, 43, pp. 2591 - 2591, http://dx.doi.org/10.1200/jco.2025.43.16_suppl.2591

Butler MO; Sacco JJ; Khan S; Orloff MM; Patel SP; Sullivan RJ; Shoushtari AN; Marr BP; Shackleton MJ; Shields CL; Krema H; Lim L-A; Conway M; Young L; Gwadry-Sridhar FH; Joshua AM; Carvajal RD, 2025, 'Global practice patterns and outcomes for metastatic uveal melanoma treated regionally versus systemically.', Journal of Clinical Oncology, 43, http://dx.doi.org/10.1200/jco.2025.43.16_suppl.e23324

Yu EY; Ferrario C; Linch MD; Stoeckle M; Laguerre B; Arranz JA; Todenhöfer T; Fong PC; Piulats JM; Berry W; Emmenegger U; Mourey L; Joshua AM; Mar N; Appleman LJ; Conter HJ; Gravis G; Li XT; Schloss C; Poehlein C; de Bono JS, 2025, 'Pembrolizumab plus Abiraterone Acetate and Prednisone in Patients with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Results from KEYNOTE-365 Cohort D.', Eur Urol Oncol, 8, pp. 641 - 651, http://dx.doi.org/10.1016/j.euo.2024.05.013

Emmett L; Papa N; Subramaniam S; Crumbaker M; Joshua AM; Nguyen A; Weickhardt AJ; Lee ST; Ng S; Francis RJ; Goh JC; Pattison DA; Tan TH; Kirkwood ID; Hofman MS; Sandhu S; Martin AJ; Thomas H; Davis ID; Stockler MR, 2025, 'Predictive and prognostic value of baseline PSMA-PET total tumor volume and SUV mean within ENZA-p, a randomized phase II trial of enzalutamide versus enzalutamide plus [ ¹⁷⁷ Lu] Lu-PSMA-617 (ANZUP1901).', Journal of Clinical Oncology, 43, pp. 5011 - 5011, http://dx.doi.org/10.1200/jco.2025.43.16_suppl.5011

Sabahi Z; Papa N; Fendler WP; Nguyen A; Wong K; Ayati N; Ho B; Chen J; Cusick T; Burger I; Crumbaker M; Marx GM; Sharma S; Frydenberg M; Sandhu S; Davis ID; Stockler MR; Sweeney C; Joshua AM; Emmett L, 2025, 'Prognostic value of PSMA PET against CHAARTED criteria in an ENZAMET sub-cohort.', Journal of Clinical Oncology, 43, pp. 5091 - 5091, http://dx.doi.org/10.1200/jco.2025.43.16_suppl.5091

Khoja L; Atenafu EG; Joshua AM, 2025, 'Updated analyses from a global meta-analysis in metastatic uveal melanoma (mUM) to determine progression free and overall survival benchmarks by line of therapy: An international rare cancers initiative (IRCI) ocular melanoma study.', Journal of Clinical Oncology, 43, pp. 9539 - 9539, http://dx.doi.org/10.1200/jco.2025.43.16_suppl.9539

Thavaneswaran S; Lin F; Grady JP; Espinoza D; Huang ML; Chinchen S; Sebastian L; Kansara M; Mersiades T; Lee CK; Desai J; Grimison P; Brown M; Millward M; Harrup R; O’Byrne K; Nagrial A; Craft P; Simes J; Joshua AM; Thomas DM, 2024, 'A signal-seeking phase 2 study of Trastuzumab emtansine in tumours harbouring HER2 amplification or mutation', Npj Precision Oncology, 8, http://dx.doi.org/10.1038/s41698-024-00698-4

Azad AA; Bressel M; Tan H; Voskoboynik M; Suder A; Weickhardt AJ; Guminski A; Francis RJ; Saghebi J; Dhiantravan N; Joshua AM; Emmett L; Horvath L; Murphy DG; Hsiao E; Balakrishnar B; Lin P; Redfern A; Macdonald W; Ng S; Lee ST; Pattison DA; Nadebaum D; Kirkwood ID; Hofman MS; Akhurst T; Alipour R; Au L; Banks P; Emerson B; Hussain N; Haskali M; Lewin J; Linklater R; Kostos L; Kashyap R; Krishanth P; Kong G; Kumar A; Murphy D; Roselt P; Sandhu S; Scalzo M; Tran B; Wallace R; Spain L; Bourke H; Milton A; Russo D; Bills M; Chew C; Hsieh W; Crouch B; Smyth D; Pandelus S; Lam H; Gan C; Goh J; Scott A; Hafeez U; Ackermann U; Young K; Poon A; Pathmaraj K; Schembri G; Roach P; Bailey D; Hung T; Asad A; Hagan T; Watts J; Campbell E; Chua W; Pal A; Crumbaker M; Nguyen A; Yam A; Chen J; Ardolino L; Kongrak K; Ratnayake L, 2024, 'Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study', Lancet Oncology, 25, pp. 1267 - 1276, http://dx.doi.org/10.1016/S1470-2045(24)00440-6

O'Day RF; Conway RM; Lim LA; Giblin M; Cherepanoff S; Joshua A; McKay D; McKenzie JD; Fog LS; Holly P; Shackleton M; Kee D; Philips C; McKelvie P; Bhikoo R; Hadden P; Negretti GS; Sagoo MS; Damato BE; Sia D; McGrath L; Glasson W; Isaacs T; Gillies M; Barthelmes D, 2024, 'The Fight Tumour Blindness Registry: Efficient capture of high-quality real-world data in uveal melanoma', Canadian Journal of Ophthalmology, 59, pp. e525 - e533, http://dx.doi.org/10.1016/j.jcjo.2024.05.006

Tan Q; Joshua AM; Wang M; Bristow RG; Wouters BG; Allen CJ; Tannock IF, 2024, 'Correction to: Up-regulation of autophagy is a mechanism of resistance to chemotherapy and can be inhibited by pantoprazole to increase drug sensitivity (Cancer Chemotherapy and Pharmacology, (2017), 79, 5, (959-969), 10.1007/s00280-017-3298-5)', Cancer Chemotherapy and Pharmacology, 94, pp. 485 - 486, http://dx.doi.org/10.1007/s00280-023-04636-2

Li S; Nguyen A; Counter W; John NC; De Leon J; Hruby G; Joshua AM; Stricker P; Crumbaker M; Ayati N; Chan L; Sabahi Z; Swiha M; Kneebone A; Wong K; Liu V; Sharma S; Agrawal S; Emmett LM, 2024, 'Utility of 64Cu-Sarcophagine-Bombesin PET/CT in Men with Biochemically Recurrent Prostate Cancer and Negative or Equivocal Findings on 68Ga-PSMA-11 PET/CT', Journal of Nuclear Medicine, 65, pp. 1371 - 1375, http://dx.doi.org/10.2967/jnumed.124.267881

Fleshner NE; Bernardino RM; Lajkosz K; Saad F; Izawa J; Drachenberg D; Saranchuk JW; Tanguay S; Rendon RA; Leveridge M; Shayegan B; Fairey A; Cockburn JG; Berlin D; Hamilton RJ; Sildva T; Breau RH; Richard PO; Klotz L; Joshua AM, 2024, 'A randomized, double-blind, placebo-controlled trial of metformin in reducing progression among men on expectant management for low-risk prostate cancer: The MAST (Metformin Active Surveillance Trial) study.', Journal of Clinical Oncology, 42, pp. LBA5002 - LBA5002, http://dx.doi.org/10.1200/jco.2024.42.17_suppl.lba5002

Joshua AM; O'day R; Glasson W; Sia D; McGrath L; Ameratunga M; Cosman R; Cherepanoff S; O'Quigley M; Beaupre DM; Conway M; Lim L-A; McKenzie J; McKay D; Shackleton MJ; Fung A; Isaacs T; Yousif J; Brooks C; Psaroulis T, 2024, 'A phase 2 safety and efficacy study of neoadjuvant/adjuvant darovasertib for localized ocular melanoma.', Journal of Clinical Oncology, 42, pp. 9510 - 9510, http://dx.doi.org/10.1200/jco.2024.42.16_suppl.9510

Kwan EM; Hofman MS; Ng SWS; Emmett L; Sandhu S; Buteau JP; Iravani A; Joshua AM; Francis RJ; Subhash V; Lee ST; Scott AM; Martin AJ; Stockler MR; Donnellan G; Annala M; Tolmeijer SH; Azad A; Davis ID; Wyatt AW, 2024, 'Circulating tumour DNA fraction as a predictor of treatment efficacy in a randomized phase 2 trial of [¹⁷⁷Lu]Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel (TheraP ANZUP 1603).', Journal of Clinical Oncology, 42, pp. 5055 - 5055, http://dx.doi.org/10.1200/jco.2024.42.16_suppl.5055

Liu JJ; Minchom AR; Greystoke A; Evans TRJ; Sarker D; Joshua AM; Morton C; Aktas BY; Cosman R; Chwialkowska D; Paull J; Main NJ; Jean-Francois BM; Le Meur J; Edmondson SR; Cook N, 2024, 'Dendrimer-enhanced (DEP) SN38 (DEP irinotecan) in patients (pts) with advanced solid tumors: A phase 1/2 trial.', Journal of Clinical Oncology, 42, pp. 3014 - 3014, http://dx.doi.org/10.1200/jco.2024.42.16_suppl.3014

Spicer JF; Pinato DJ; Forster M; Joshua AM; Korolewicz J; Aboud K; Morton C; Liu JJ; Cosman R; Main NJ; Le Meur J; Paull J; Edmondson SR; Jones RH, 2024, 'Efficacy and safety of dendrimer-enhanced (DEP) cabazitaxel (DEP CTX) in patients with advanced solid cancers in a phase 1/2 trial (P1/2).', Journal of Clinical Oncology, 42, pp. 3004 - 3004, http://dx.doi.org/10.1200/jco.2024.42.16_suppl.3004

Wheatley DA; Berardi R; Climent Duran MA; Tomiak A; Greystoke AP; Joshua AM; Arkenau HT; Géczi L; Corbacho JG; Paz-Ares LG; Hussain SA; Petruželka L; Delmonte A; Chappey C; Masters JC; Michelon E; Murphy DA; Mwewa S; Cesari R; de Spéville BD, 2024, 'First-line Avelumab plus Chemotherapy in Patients with Advanced Solid Tumors: Results from the Phase Ib/II JAVELIN Chemotherapy Medley Study', Cancer Research Communications, 4, pp. 1609 - 1619, http://dx.doi.org/10.1158/2767-9764.CRC-23-0459

Ng CA; Luckett T; Mulhern B; Kee D; Lai-Kwon J; Joshua AM, 2024, 'What matters most to people with metastatic uveal melanoma? A qualitative study to inform future measurement of health-related quality of life', Melanoma Research, 34, pp. 248 - 257, http://dx.doi.org/10.1097/CMR.0000000000000961

Emmett L; Subramaniam S; Crumbaker M; Nguyen A; Joshua AM; Weickhardt A; Lee ST; Ng S; Francis RJ; Goh JC; Pattison DA; Tan TH; Kirkwood ID; Gedye C; Rutherford NK; Sandhu S; Kumar AR; Pook D; Ramdave S; Nadebaum DP; Voskoboynik M; Redfern AD; Macdonald W; Krieger L; Schembri G; Chua W; Lin P; Horvath L; Bastick P; Butler P; Zhang AY; Yip S; Thomas H; Langford A; Hofman MS; McJannett M; Martin AJ; Stockler MR; Davis ID, 2024, '[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial', Lancet Oncology, 25, pp. 563 - 571, http://dx.doi.org/10.1016/S1470-2045(24)00135-9

Tan Q; Joshua AM; Saggar JK; Yu M; Wang M; Kanga N; Zhang JY; Chen X; Wouters BG; Tannock IF, 2024, 'Retraction Note: Effect of pantoprazole to enhance activity of docetaxel against human tumour xenografts by inhibiting autophagy (British Journal of Cancer, (2015), 112, 5, (832-840), 10.1038/bjc.2015.17)', British Journal of Cancer, 130, pp. 1232, http://dx.doi.org/10.1038/s41416-024-02660-4

Hiong A; O'Day R; Fog LS; McKay D; McKenzie J; Ameratunga M; Joshua AM; Shackleton M, 2024, 'Globe Salvage and Vision Preservation by Neoadjuvant Darovasertib and Crizotinib in Uveal Melanoma', Ophthalmology Retina, 8, pp. 325 - 330, http://dx.doi.org/10.1016/j.oret.2023.10.009

Zhang J; Joshua AM; Li Y; O'Meara CH; Morris MJ; Khachigian LM, 2024, 'Targeted therapy, immunotherapy, and small molecules and peptidomimetics as emerging immunoregulatory agents for melanoma', Cancer Letters, 586, http://dx.doi.org/10.1016/j.canlet.2024.216633

Conduit C; Davis ID; Goh JC; Kichenadasse G; Gurney H; Harris CA; Pook D; Krieger L; Parnis F; Underhill C; Adams D; Roncolato F; Joshua A; Ferguson T; Prithviraj P; Morris M; Harrison M; Begbie S; Hovey E; George M; Liow EC; Link EK; McJannett M; Gedye C, 2024, 'A phase II trial of nivolumab followed by ipilimumab and nivolumab in advanced non-clear-cell renal cell carcinoma', BJU International, 133, pp. 57 - 67, http://dx.doi.org/10.1111/bju.16190

Yu EY; Joshua AM; Kramer G; Shore ND; Hu H; Poehlein CH; Schloss C; De Bono JS, 2024, 'Phase 1b/2 study of pembrolizumab (pembro) plus platinum/etoposide and platinum/etoposide for neuroendocrine metastatic prostate cancer (NEPC): KEYNOTE-365 cohort I.', Journal of Clinical Oncology, 42, pp. TPS249 - TPS249, http://dx.doi.org/10.1200/jco.2024.42.4_suppl.tps249

Yu EY; Joshua AM; Shore ND; Kramer G; Hu H; Poehlein CH; Schloss C; De Bono JS, 2024, 'Phase 1b/2 study of pembrolizumab plus belzutifan and belzutifan alone in patients with docetaxel-treated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort J.', Journal of Clinical Oncology, 42, pp. TPS250 - TPS250, http://dx.doi.org/10.1200/jco.2024.42.4_suppl.tps250

Back to profile page